6490 Microalbuminuria and Steatotic Liver Disease in Patients with Type 2 Diabetes: A Retrospective Cross-Sectional Study in Mexico City

Abstract Disclosure: F. Martinez-Sanchez: None. A. Diaz-Jarquin: None. S. Feria-Agudelo: None. M. Corredor-Nassar: None. C. Martinez-Perez: None. Z. Soto-Montes: None. V. Vargas-Abonce: None. V. Paz-Zarza: None. G. Gonzalez-Alvarez: None. E. Tenorio-Aguirre: None. J. Cordova-Gallardo: None. N. Mendez-Sanchez: None. Introduction: Microalbuminuria (MAU) is an independent cardiovascular risk factor in patients with type 2 diabetes. Albuminuria has been associated with increased hepatic steatosis in various population studies, with conflicting results. Although the definition of Metabolic dysfunction associated steatotic liver disease (MASLD) has been modified in recent years, the relationship between MASLD and albuminuria in patients with type 2 diabetes has not been fully yielded. Objective: To evaluate the association between MAU and hepatic steatosis in patients with type 2 diabetes. Materials and Methods: Retrospective cross-sectional observational study of 1115 patients with type 2 diabetes. The data were collected from the internal medicine outpatient clinic from 2018 to 2023. Clinical and biochemical data were also collected. Patients with ICD-10 codes for alcoholism and alcoholic hepatitis were excluded. MAU was determined by 24-hour urine collection. Hepatic steatosis was defined by a Fatty Liver Index (FLI) > 60. Binary logistic regression analysis was used to determine the independent association between MAU and hepatic steatosis. Results: The mean age of the patients was 59.6 ± 14.1 years, 68.2% were women, the mean body mass index (BMI) was 28.6 ± 6.2 kg/m2, and had a mean waist circumference of 88 ± 16.6 cm. The median duration of diabetes before the first medical consultation at our institution was 7 (3-14) years. The median FLI was 61 (35 - 83), and median MAU was 9.44 (2.14 – 49.95) mg/24h; 71.7%, 20.1%, and 8.2% had MAU in <30, 30-300, and >300 mg/24h, respectively. Multivariate analysis showed that having 30-300 and >300 mg/24h of MAU had an Odds Ratio of 4.317 (2.485 – 7.500) and 5.480 (2.306 - 13.023) for hepatic steatosis. Conclusion: Microalbuminuria was associated with increased odds for hepatic steatosis in patients with type 2 diabetes, independently of age, sex, hemoglobin A1c, duration of diabetes, glucose-lowering drugs (metformin, insulin, SGLT-2i, GLP-1, DPP-4i, thiazolidinediones, and sulfonylureas), fibrates, statins, total cholesterol, and serum creatinine. The results cannot determine whether MAU is a risk factor for hepatic steatosis or vice versa. Prospective cohort studies are required to determine if there is a risk between both entities. Presentation: 6/2/2024